Scynexis Initial Public Offering

Cooley advised Scynexis, Inc. on its $62 million initial public offering of 6,200,000 shares of common stock. The underwriters have a 30-day option to purchase an additional 930,000 shares. Partners Matthew Hemington and Brett White led the Cooley team advising Scynexis.

RBC Capital Markets, Canaccord Genuity and JMP Securities acted as joint book-running managers for the offering.

Scynexis is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. The company’s shares now trade on the Nasdaq Global Market under the symbol “SCYX.”

Related Contacts
Matthew Hemington Partner, Palo Alto
Brett White Of Counsel, Palo Alto
Related Practices & Industries

Capital Markets Public Companies Life Sciences